Vyome

News & Media

Stay up to date with the latest press releases, media coverage, and company updates from Vyome Holdings.

Vyome Holdings Announces Positive Interim Data from Phase 2 Study of VT-1953 in Malignant Fungating Wounds (MFW)

Sep 4, 2025

Vyome Announces Strategic Review of Livechain (OTCID: LICH)

Aug 18, 2025

Vyome To Mark First Day of Trading as HIND with Nasdaq Opening Bell

Aug 15, 2025

Vyome Closes Merger Transaction, Will Trade on Nasdaq as HIND Tomorrow

Aug 14, 2025

Checkerboard Analysis To Evaluate Synergistic Combinations of Existing Antifungal Drugs and Propylene Glycol Monocaprylate in Isolates from Recalcitrant Tinea Corporis and Cruris Patients Harboring Squalene Epoxidase Gene Mutation

Sardana K, Gupta A, Sadhasivam S, Gautam RK, Khurana A, Saini S, Gupta S, Ghosh S. Antimicrob Agents Chemother.

Mechanistic Insight Into the Antifungal Effects of a Fatty Acid Derivative Against Drug-Resistant Fungal Infections

Bhattacharyya A, Sinha M, Singh H, Patel RS, Ghosh S, Sardana K, Ghosh S, Sengupta S. Front Microbiol.

Vyome Announces Nasdaq Approval of Merger with ReShape Lifesciences, Set to Begin Trading as HIND

Aug 13, 2025

Vyome Announces New Board of Directors with Deep MIT and AI Ties

Aug 12, 2025

ReShape Lifesciences Announces Shareholder Approval of Merger with Vyome Therapeutics

Aug 7, 2025

Antibiotic-resistant acne: getting under the skin

Sinha M, Sadhasivam S, Bhattacharyya A, Jain S, Ghosh S, Arndt KA, Dover JS, Sengupta S. Semin Cutan Med Surg.

Heterogeneity and antibiotic resistance in Propionibacterium acnes isolates and its therapeutic implications: blurring the lines between commensal and pathogenic phylotypes

Sadhasivam S, Sinha M, Saini S, Kaur SP, Gupta T, Sengupta S, Ghosh S, Sardana K. Dermatol Ther.

ReShape Lifesciences® Announces Partial Adjournment of Special Meeting of Stockholders

Jul 24, 2025

ReShape Lifesciences® to Host Special Meeting of Stockholders on July 24, 2025

Jul 21, 2025

ReShape Lifesciences® Announces Strategic Cost Reductions and Provides Update on the Merger Agreement with Vyome Therapeutics and Asset Purchase Agreement with Biorad Medisys

Jun 26, 2025

ReShape Lifesciences® Reports Year Ended December 31, 2024 Financial Results and Provides Corporate Update

Apr 7, 2025

Vyome Therapeutics Presents Positive Data from Early Analysis of a Phase 2 Study of VT-1953 in Malignant Fungating Wound

Jan 22, 2025

ReShape Lifesciences® Provides Update on Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys

Jan 13, 2025

Vyome Therapeutics featured on Yahoo! Finance

Jan 9, 2025

Vyome to go public and trade on the Nasdaq Capital Market under the ticker symbol 'HIND'

Jul 9, 2024

ReShape Lifesciences® Enters Into Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys

Jul 9, 2024

Disclaimer

*Certain statements on this site are forward-looking within the meaning of federal securities laws. Please see our full disclaimer here.

A Cambridge, MA, based global healthcare platform synergizing biotech, medical devices, and AI.

Vyome Holdings, Inc.
Nasdaq: HIND

PRINCIPAL OFFICE

Harvard Square, One Mifflin Place, Suite 400, Cambridge, MA 02138

PHONE

+1 973-832-8147

SUBSIDIARIES

⁠Vyome Therapeutics, Inc.

OFFICE

Harvard Square, One Mifflin Place, Suite 400, Cambridge, MA 02138

Vyome Therapeutics Limited, Subsidiary of Vyome Therapeutics, Inc.

OFFICE

Plot No. 465, Ground Floor, F.I.E., Patparganj Industrial Area, Delhi, India- 110092.

PHONE

+91-99682-17333

*Certain statements on this site are forward-looking within the meaning of federal securities laws. Please see our full disclaimer here.

Home

ABOUT

Management

Board Members

Company Vision

SCIENCE & PIPELINE

Pipeline

Publications

INVESTORS

Investor Home

Quarterly Results

Committees

News & Media

Contact

A Cambridge, MA, based global healthcare platform synergizing biotech, medical devices, and AI.

Vyome Holdings, Inc.
Nasdaq: HIND

PRINCIPAL OFFICE

Harvard Square, One Mifflin Place, Suite 400, Cambridge, MA 02138

PHONE

+1 973-832-8147

SUBSIDIARIES

⁠Vyome Therapeutics, Inc.

OFFICE

Harvard Square, One Mifflin Place, Suite 400, Cambridge, MA 02138

Vyome Therapeutics Limited, Subsidiary of Vyome Therapeutics, Inc.

OFFICE

Plot No. 465, Ground Floor, F.I.E., Patparganj Industrial Area, Delhi, India- 110092.

PHONE

+91-99682-17333

*Certain statements on this site are forward-looking within the meaning of federal securities laws. Please see our full disclaimer here.

Home

ABOUT

Management

Board Members

Company Vision

SCIENCE & PIPELINE

Pipeline

Publications

INVESTORS

Investor Home

Quarterly Results

Committees

News & Media

Contact

Vyome Holdings, Inc.
Nasdaq: HIND

PRINCIPAL OFFICE

Harvard Square, One Mifflin Place, Suite 400, Cambridge, MA 02138

PHONE

+1 973-832-8147

SUBSIDIARIES

⁠Vyome Therapeutics, Inc.

OFFICE

Harvard Square, One Mifflin Place, Suite 400, Cambridge, MA 02138

Vyome Therapeutics Limited, Subsidiary of Vyome Therapeutics, Inc.

OFFICE

Plot No. 465, Ground Floor, F.I.E., Patparganj Industrial Area, Delhi, India- 110092.

PHONE

+91-99682-17333

*Certain statements on this site are forward-looking within the meaning of federal securities laws. Please see our full disclaimer here.

Home

ABOUT

Management

Board Members

Company Vision

SCIENCE & PIPELINE

Pipeline

Publications

INVESTORS

Investor Home

Quarterly Results

Committees

News & Media

Contact